Piper Sandler raised the firm’s price target on Halozyme (HALO) to $53 from $52 and keeps a Neutral rating on the shares after maintaining FY24 ...

H.C. Wainwright raised the firm’s price target on Halozyme (HALO) to $70 from $68 and keeps a Buy rating on the shares. The company has strong ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Wells Fargo has recently reduced Halozyme Therapeutics, Inc. (HALO) stock to Equal Weight rating, as announced on October 7, 2024, according to Finviz. Earlier, on September 19, 2024, JP Morgan had ...

Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday ...

January 05, 2025, 00:04 am ET, BY Joseph H.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Becomes the first subcutaneously administered PD-1 inhibitor.